ono4819 has been researched along with Osteoporosis* in 3 studies
1 review(s) available for ono4819 and Osteoporosis
Article | Year |
---|---|
Emerging targets in osteoporosis disease modification.
Topics: Animals; Biomarkers; Bone Density; Bone Resorption; Humans; Osteoporosis | 2010 |
2 other study(ies) available for ono4819 and Osteoporosis
Article | Year |
---|---|
Prostaglandin EP4 receptor agonist augments fixation of hydroxyapatite-coated implants in a rat model of osteoporosis.
The reduced stability of hydroxyapatite (HA)-coated implants in osteopenic conditions is considered to be a major problem. We therefore developed a model of a boosted cementless implantation in osteopenic rats.Twelve-week-old rats were either ovariectomised (OVX) or sham-operated (SO), and after 24 weeks plain or HA-coated implants were inserted. They were treated with either a prostaglandin EP4 receptor agonist (ONO-4819) or saline for one month. The EP4 agonist considerably improved the osteoporosis in the OVX group. Ultrastructural analysis and mechanical testing showed an improvement in the implant-bone attachment in the HA-coated implants, which was further enhanced by the EP4 agonist. Although the stability of the HA-coated implants in the saline-treated OVX rats was less than in the SO normal rats, the administration of the EP4 agonist significantly compensated for this shortage. Our results showed that the osteogenic effect of the EP4 agonist augmented the osteoconductivity of HA and significantly improved the stability of the implant-bone attachment in the osteoporotic rat model. Topics: Animals; Arthroplasty, Replacement, Hip; Bone Density; Coated Materials, Biocompatible; Disease Models, Animal; Durapatite; Female; Femur; Heptanoates; Osseointegration; Osteoporosis; Ovariectomy; Rats; Rats, Wistar; Receptors, Prostaglandin E; Receptors, Prostaglandin E, EP4 Subtype | 2005 |
Stimulation of bone formation and prevention of bone loss by prostaglandin E EP4 receptor activation.
Bone remodeling, comprising resorption of existing bone and de novo bone formation, is required for the maintenance of a constant bone mass. Prostaglandin (PG)E2 promotes both bone resorption and bone formation. By infusing PGE2 to mice lacking each of four PGE receptor (EP) subtypes, we have identified EP4 as the receptor that mediates bone formation in response to this agent. Consistently, bone formation was induced in wild-type mice by infusion of an EP4-selective agonist and not agonists specific for other EP subtypes. In culture of bone marrow cells from wild-type mice, PGE2 induced expression of core-binding factor alpha1 (Runx2/Cbfa1) and enhanced formation of mineralized nodules, both of which were absent in the culture of cells from EP4-deficient mice. Furthermore, administration of the EP4 agonist restored bone mass and strength normally lost in rats subjected to ovariectomy or immobilization. Histomorphometric analysis revealed that the EP4 agonist induced significant increases in the volume of cancellous bone, osteoid formation, and the number of osteoblasts in the affected bone of immobilized rats, indicating that activation of EP4 induces de novo bone formation. In addition, osteoclasts were found on the increased bone surface at a density comparable to that found in the bone of control animals. These results suggest that activation of EP4 induces bone remodeling in vivo and that EP4-selective drugs may be beneficial in humans with osteoporosis. Topics: Animals; Bone Resorption; Cells, Cultured; Dinoprostone; Female; Male; Mice; Mice, Inbred C57BL; Osteoblasts; Osteogenesis; Osteoporosis; Ovariectomy; Rats; Rats, Sprague-Dawley; Receptors, Prostaglandin E; Receptors, Prostaglandin E, EP4 Subtype | 2002 |